利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18336 条记录 (耗时 0.047 秒)

    METHOD AND KIT FOR ASSISTING IN DETERMINATION OF MALIGNANT PANCREATIC CYSTIC TUMOR
    86.
    发明公开
    METHOD AND KIT FOR ASSISTING IN DETERMINATION OF MALIGNANT PANCREATIC CYSTIC TUMOR 审中-公开

    公开(公告)号：US20240168026A1

    公开(公告)日：2024-05-23

    申请号：US18283274

    申请日：2022-03-22

    申请人： Toray Industries, Inc. ,  NATIONAL CANCER CENTER

    发明人： Michimoto Kobayashi ,  Hideki Kawai ,  Asako Sogame ,  Kazufumi Honda

    IPC分类号： G01N33/574 ,  C07K16/18

    CPC分类号： G01N33/57438 ,  C07K16/18

    摘要： The present invention provides a convenient and noninvasive detection method for assisting in the determination of pancreatic cystic tumor to be benign or malignant, and a kit for detection therefor. Specifically, the present invention provides a method for assisting in the determination of malignant pancreatic cystic tumor, the method comprising the steps of measuring in vitro the amount of APOA2-AT protein or/and APOA2-ATQ protein present in a body fluid sample of a test subject having pancreatic cystic tumor, and assisting in determining the pancreatic cystic tumor to be benign or malignant on the basis of the amount, and a kit for assisting in the determination of malignant pancreatic cystic tumor, the kit being directed to measuring the amount of APOA2-AT protein or/and APOA2-ATQ protein and being usable in the method.

    METHOD FOR DIAGNOSING PANCREATIC CANCER
    88.
    发明公开
    METHOD FOR DIAGNOSING PANCREATIC CANCER 审中-公开

    公开(公告)号：US20240159760A1

    公开(公告)日：2024-05-16

    申请号：US18550831

    申请日：2022-03-16

    申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER ,  UNIVERSITÉ DE MONTPELLIER ,  CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER

    发明人： Andrei TURTOI ,  François-Régis SOUCHE ,  Guillaume TOSATO ,  Jacques COLINGE

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57438

    摘要： The present invention relates to the diagnostics of pancreatic cancer. The inventors engineered a novel biomarker discovery approach, tailored for PDAC, which is all-patient inclusive, termed PanEXPEL. This approach offers access to PDAC clinical material before any treatment is applied. The method benefits from clinical biopsy, yet does not interfere with that diagnostic procedure. It can be integrated seamlessly into clinical routine, and is compatible with any type of OMICS profiling. PanEXPEL relies on the interstitial tissue fluid released from the lesion during diagnostic biopsy by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA). This is the first technique that allows both clinicians and researchers to analyze identical material in the field of proteomics biomarker research. Here, they demonstrate the potential of PanEXPEL methodology by identifying a PDAC early detection signature through proteomics and subsequent statistical learning. Thus, the present invention relates to a method for diagnosing a pancreatic cancer in a subject in need thereof comprising determining in a sample obtained from the subject the expression levels of at least one biomarker selected from the group consisting of AGR2, ANXA2, ANXA3, ANXA4, CECAM6, CYP2S1, DMBT1, KRT7, KRT8, KRT17, KRT18, KRT19, MAL2, MYH14, 0LFM4, PIGR, SERPINB5, SERPINH1, and TIMP1.

    LUNG CANCER DIAGNOSIS USING BIOMARKERS FROM EXOSOMES
    89.
    发明公开
    LUNG CANCER DIAGNOSIS USING BIOMARKERS FROM EXOSOMES 审中-公开

    公开(公告)号：US20240159754A1

    公开(公告)日：2024-05-16

    申请号：US18280866

    申请日：2022-03-07

    申请人： TERASOM S.R.O.

    发明人： Daniela PANKOVA

    IPC分类号： G01N33/574 ,  G01N33/543

    CPC分类号： G01N33/57423 ,  G01N33/54387

    摘要： The present invention relates to the diagnosis of lung cancer in a subject. The invention provides a diagnostic method of obtaining an indication of the presence of lung cancer in a subject, based on the presence of one or more biomarkers which are present in or on the surface of exosomes or are cleaved exosomal surface polypeptides obtained from a liquid biopsy or other biological sample. The invention also provides devices, such as flow and microfluidics devices, which may be used for diagnosis of lung cancer in a subject.

    METHODS FOR COLORECTAL CANCER DIAGNOSIS AND PROGNOSIS
    90.
    发明公开
    METHODS FOR COLORECTAL CANCER DIAGNOSIS AND PROGNOSIS 审中-公开

    公开(公告)号：US20240159752A1

    公开(公告)日：2024-05-16

    申请号：US18171399

    申请日：2023-02-20

    申请人： Chang Gung University

    发明人： Jau-Song YU ,  Srinivas DASH ,  Chia-Chun WU ,  Sheng-Fu CHIANG ,  Yu-Ting LU

    IPC分类号： G01N33/574 ,  G01N33/534 ,  G01N33/68

    CPC分类号： G01N33/57419 ,  G01N33/534 ,  G01N33/6893 ,  G01N2800/7028

    摘要： Disclosed herein is a method for determining whether a subject has or is at risk of developing colorectal cancer with an ex vivo biological sample isolated from the subject. The method comprises: determining the levels of at least two target proteins with the aid of mass spectrometry, in which the at least two target proteins are selected from the group consisting of ADAM10, CD59, and TSPAN9; and assessing whether the subject has or is at risk of developing the colorectal cancer based on the levels of the at least two target proteins. The present method may serve as a potential means for diagnosing and predicting the incidence of colorectal cancer, and the subject in need thereof could receive a suitable therapeutic regimen in time in accordance with the diagnostic results produced by the present method.